Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Chlorine Dioxide Injection 2% in Advanced Extracranial Solid Tumors
NCT07911293Phase 1Not yet recruiting
- Sponsor
- SunGlow Innovations
- Start
- Mar 2027
- Primary completion
- Mar 2028
01
Overview
Phase 1, open-label, single-arm trial of CloSYS Oral Rinse in solid tumor, sponsored by SunGlow Innovations. Primary endpoints: Dose-limiting toxicities at 28 days, Treatment-emergent adverse events at 12 months and 6 more. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
CloSYS Oral Rinse
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07911293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07911293.